

HER2 Expression and Survival Outcomes in Gastric Adenocarcinoma: Association with Clinical, Endoscopic, and Histopathological Features

By Deka Larasati

ORIGINAL ARTICLE

HER2 Expression and Survival Outcomes in Gastric Adenocarcinoma: Association with Clinical, Endoscopic, and Histopathological Features

ABSTRACT

Background: HER2 is a proto-oncogene and therapeutic target in advanced gastric adenocarcinoma. Studies on its association with clinicopathological features and prognosis remain inconsistent. This study aimed to evaluate the relationship of clinical, endoscopic, and histopathological features with HER2 expression and its impact on two-year survival.

Methods: A retrospective cohort was conducted on patients ≥ 18 years with newly diagnosed gastric adenocarcinoma at four Jakarta hospitals (2015–2019). Eligible cases had complete records and paraffin blocks. HER2 was assessed by immunohistochemistry and CISH using ToGA criteria. Chi-square/Fisher's tests evaluated associations, while survival was analysed with Kaplan-Meier and Cox regression.

Results: Among 122 patients, 15 (12.3%) were HER2-positive. Expression tended to be higher in cases with liver metastasis, Borrmann type I/II, moderate differentiation, and intestinal type, but none were statistically significant. Median survival was 5 months in HER2-positive and 4 months in HER2-negative patients. HER2 was not significantly associated with two-year survival (HR 1.12; 95% CI 0.61–2.06).

Conclusion: Clinicopathological features were not associated with HER2 expression, and HER2 status was not a prognostic factor for two-year survival in gastric adenocarcinoma.

Keywords: clinicopathological features, gastric adenocarcinoma, HER2, survival.

ABSTRAK

Latar Belakang: HER2 merupakan protoonkogen yang berperan penting sekaligus menjadi sasaran terapi pada adenokarsinoma gaster stadium lanjut. Namun, bukti mengenai keterkaitan HER2 dengan faktor klinis, endoskopi, histopatologi, maupun prognosis masih belum konsisten. Penelitian ini bertujuan mengevaluasi hubungan karakteristik klinis, endoskopi, dan histopatologi dengan ekspresi HER2, serta dampaknya terhadap kesintasan dua tahun.

Metode: Studi kohort retrospektif dilakukan pada pasien ≥ 18 tahun dengan diagnosis baru adenokarsinoma gaster di empat rumah sakit di Jakarta selama periode 2015–2019. Subjek yang memenuhi syarat memiliki rekam medis lengkap dan blok parafin yang tersedia. Ekspresi HER2 dianalisis menggunakan imunohistokimia dan dikonfirmasi dengan CISH berdasarkan kriteria ToGA. Hubungan antara variabel diuji dengan Chi-square/Fisher, sedangkan kesintasan dinilai menggunakan Kaplan-Meier dan regresi Cox.

Hasil: Dari 122 pasien, 15 (12,3%) HER2-positif. Ekspresi cenderung lebih tinggi pada kasus dengan metastasis hati, tipe Borrmann I/II, diferensiasi sedang, dan tipe intestinal, namun tidak bermakna secara statistik. Median kesintasan adalah 5 bulan pada HER2-positif dan 4 bulan pada HER2-negatif. Tidak terdapat hubungan bermakna antara ekspresi HER2 dan kesintasan dua tahun (HR 1,12; IK95% 0,61–2,06).

Simpulan: Faktor klinis, endoskopi, dan histopatologi tidak berhubungan dengan ekspresi HER2. Ekspresi HER2 bukan faktor prognostik kesintasan dua tahun pada adenokarsinoma gaster.

Kata kunci: adenokarsinoma gaster, HER2 karakteristik klinis, kesintasan.

Introduction

Globally, gastric cancer ranks fourth for incidence and second for mortality. Around 990,000 new cases and 738,000 deaths occur each year, men and populations in developing

countries are disproportionately affected^(1–3). Five-year survival varies widely, about 10–30% in Europe but higher in Japan due to endoscopic screening⁽⁴⁾. In Indonesia, it ranks 19th by incidence; five-year prevalence is 1.4 per 100,000 and most patients present at advanced stages; adenocarcinoma predominates^(5,6).

Survival variation among patients with the same stage highlights the role of biological factors beyond clinical staging, including molecular markers such as HER2. This proto-oncogene regulates proliferation, apoptosis, and angiogenesis and is overexpressed in 6–30% of gastric cancers^(7,8). HER2 expression differs according to tumor site, histology, stage, and geography⁽⁹⁾. Several studies reported higher expression in intestinal-type adenocarcinoma and an association with poor prognosis^(10,11).

Nevertheless, data regarding HER2 prevalence and prognostic value remain inconsistent. The ToGA trial reported 22% HER2 positivity⁽¹²⁾, while a meta-analysis found a median prevalence of 18% with wide variability (4–53%)⁽¹³⁾. Geographic differences are notable, with prevalence reaching 56% in Northeast India⁽¹⁴⁾, 20% in Europe and the United States⁽⁹⁾, and 9.7% in multinational Asian cohorts⁽¹⁵⁾. In Indonesia, Setiawati et al. reported a prevalence of 14.5%⁽¹⁶⁾.

Associations between HER2 expression and survival also vary. While some studies linked HER2 positivity to worse outcomes^(13,17,18), others found no prognostic significance (9). Unlike Japan, Europe, and the United States, Indonesia lacks national guidelines for HER2 testing or anti-HER2 therapy. Considering potential variability related to clinicopathological features and ethnicity, but limited local evidence^(10,19–21), further research in Indonesian populations is needed. Therefore, this study aimed to evaluate the association of clinical, endoscopic, and histopathological features with HER2 expression, and to assess the relationship between HER2 expression and two-year survival in patients with gastric adenocarcinoma.

Methods

Study Design and Setting

This study employed a retrospective cohort and cross-sectional design. The cross-sectional component was used to analyze the association between clinical, endoscopic, and histopathological features with HER2 expression at a single point in time, based on existing medical records and pathology specimens. The retrospective cohort component was applied to assess the prognostic value of HER2 expression by following patients' outcomes for two years after the initial diagnosis. Case identification, data abstraction (clinical, endoscopic, radiologic,

pathologic), and slide re-evaluation were performed from September 2020 to September 2021 across four AHS-FKUI hospitals (RSCM, RSPAD, Fatmawati, Dharmais). Paraffin blocks from tumor biopsies were reprocessed and examined using immunohistochemistry (IHC) and chromogenic in situ hybridization (CISH) were conducted centrally at the Department of Anatomical Pathology, Universitas Indonesia

Study Population and Sampling

Patients aged ≥ 18 years with histologically confirmed gastric adenocarcinoma diagnosed between 2015 and 2019 were screened from hospital registries. A total of 204 patients were initially identified across four participating hospitals. After applying inclusion criteria (availability of paraffin blocks and biopsy slides from endoscopic or surgical procedures, and no prior chemotherapy, radiotherapy, or targeted therapy at the time of biopsy) and exclusion criteria (missing or damaged slides and incomplete clinical or endoscopic records), 122 patients were eligible and included in the final analysis.

Sample size was calculated using the hypothesis test for two proportions, with the following formula:

$$n_1 = n_2 = \left(\frac{Z_{\alpha} \sqrt{2PQ} + Z_{\beta} \sqrt{P_1 Q_1 + P_2 Q_2}}{P_1 - P_2} \right)^2$$

where $Z_{\alpha} = 1.64$ (type I error 5%), $Z_{\beta} = 0.84$ (type II error 20%), P_1 and P_2 represent the proportions in HER2-positive and HER2-negative groups, respectively, $Q_1 = 1 - P_1$, $Q_2 = 1 - P_2$, $P = (P_1 + P_2)/2$, and $Q = 1 - P$.

Based on previous studies, the minimum sample size required ranged from 34 to 122 depending on the variable assessed: 60 for liver metastasis⁽²²⁾, 46 for tumor location⁽¹⁴⁾, 122 for Borrmann classification⁽²³⁾, 34 for differentiation⁽²⁴⁾, and 60 for Lauren classification⁽²⁵⁾. For survival and multivariate analyses, the largest estimate (122 subjects) was adopted. Ultimately, 122 eligible patients were included in this study.

Histopathology and HER2 Assessment

Histopathological slides were reviewed to confirm the diagnosis, classify tumors according to WHO and Lauren criteria, and determine differentiation grade. HER2 expression was evaluated using immunohistochemistry (IHC) with rabbit monoclonal HER2 antibody (Leica) and scored according to ToGA criteria^(12,26). Equivocal cases (IHC 2+) were further analyzed by chromogenic in situ hybridization (CISH) to determine gene amplification^(27,28). Breast carcinoma tissue with known HER2 positivity was used as a positive control, while

negative control was performed by omitting the primary antibody. All assessments were performed by two independent pathologists blinded to clinical data.

Statistical Analysis

Data was analyzed using SPSS version 20. Descriptive statistics were used for baseline characteristics. Associations between HER2 expression and clinicopathological variables (lesion location, morphology, liver metastasis, differentiation, and Lauren classification) were tested with Chi-square or Fisher's exact tests. Variables with $p < 0.25$ were entered into multivariate logistic regression⁽²⁹⁾. Survival was analyzed using Kaplan-Meier and Cox regression. The proportional hazards assumption was assessed with log-minus-log plots and the global test. Variables with $p < 0.25$ and clinically relevant factors were included in multivariate Cox regression. Results were expressed as hazard ratios (HR) with 95% confidence intervals (CI), with $p < 0.05$ considered statistically significant⁽³⁰⁾.

Ethical Considerations

This research received ethical clearance from the Health Research Ethics Committee, Faculty of Medicine, Universitas Indonesia – Dr. Cipto Mangunkusumo National General Hospital (Approval No. KET-1991/UN2.F1/ETIK/PPM.00.02/2020, dated December 28, 2020). All patient information was coded and de-identified to maintain confidentiality.

Results

Patient Characteristics

A total of 122 patients with gastric adenocarcinoma met the inclusion criteria (Figure 1). The mean age was 53.9 years (SD 14.4), with 63.9% aged ≤ 60 years and 57.4% male. Most patients had poor performance status (ECOG ≥ 2 in 82.0%). Liver metastasis was present in 27.9%, and tumors were evenly distributed between Cardia (46.7%) and non-Cardia regions (53.3%). Morphologically, ulcerated and diffusely infiltrative types predominated (54.1%) (Table 1).




Figure 1. Research subject selection process

Table 1. Clinical characteristics of research subjects

Variable	N=122 (%)
Age at Gastric Cancer Diagnosis	
≤ 60 years	78 (63,9)
>60 years	44 (36,1)
Gender, n (%)	
Female	52 (42,6)
Male	70 (57,4)
Educ¹² n, n (%)	
Elementary School Graduate	15 (12,3)
Junior High School Graduate	16 (13,1)
High School Graduate	65 (53,3)
Diploma/Bachelor's/Master's/Doctoral Degree Graduate	26 (21,3)
Ethnicity, n (%)	
Jawa	32 (26,2)
Batak	28 (23,0)
Cina	10 (8,3)
Sunda	24 (19,7)
Padang	3 (2,5)
Melayu	7 (5,7)
Makassar	1 (0,8)
Bali	1 (0,8)
Papua	1 (0,8)
Betawi	13 (10,7)
Buton	1 (0,8)
Dayak	1 (0,8)
ECOG at first hospital visit, n (%)	
0	4 (3,3)
1	18 (14,8)
2	34 (27,9)
3	43 (35,2)

Variable	N=122 (%)
4	23 (18,9)
Liver metastasis, n (%)	
Yes	34 (27,9)
No	88 (72,1)
Location of lesion, n (%)	
Gastric cardia	57 (46,7)
Non-gastric cardia	65 (53,3)
Lesion type based on Borrmann classification, n (%)	
Type polypoid (type I) or type fungating carcinoma (type II)	56 (45,9)
Type ulcerated (type III) or type diffusely infiltrative (type IV)	66 (54,1)
Cancer therapy	
Target cell therapy	0 (0,0)
Therapeutic resection	40 (32,8)
Palliative resection	7 (5,7)
Chemotherapy	7 (5,7)
Resection and chemotherapy	13 (10,7)
Chemotherapy and radiation	0 (0,0)
Radiation	0 (0,0)
Resection and radiation	1 (0,8)
Chemotherapy and radiation	0 (0,0)
Resection and chemoradiation	0 (0,0)
Palliative/supportive care or not further action taken	56 (45,9)
Cause of Death	
Infection	14 (14,6)
Hemorrhage	3 (3,1)
Thrombosis or embolism	0 (0,0)
Cancer-related	80 (83,3)

Histopathological Features and HER2 Expression

According to WHO classification, the majority were not otherwise specified (51.6%), followed by poorly cohesive (27.0%) and signet-ring carcinoma (10.7%). Intestinal type was more common than diffuse/mixed (59.0% vs. 41.0%), and 59.8% were poorly differentiated (Table 2).

Table 2. Histopathological characteristics

Variable	N=122 (%)
WHO Classification, n (%)	
Poorly Cohesive	33 (27,0)
NOS	63 (51,6)
Signet cel ring carcinoma	13 (10,7)
Musinosum	2 (1,6)
Tubuler	9 (7,4)
Mixed type	1 (0,8)
Papillary	1 (0,8)
Lauren Classification, n (%)	
Intestinal type	72 (59,0)
Diffuse or mixed type	50 (41,0)
Poorly Differentiated	73 (59,8)
Tumor differentiation, n (%)	
Well or moderate differentiation	49 (40,2)

Variable	N=122 (%)
Poor differentiation	73 (59,8)
HER2 Expression, n (%)	
Zero HER2 CPI result	57 (46,7)
HER2-positive CPI result 1	31 (25,4)
HER2-positive CPI result 2	21 (17,4)
HER2-positive CPI result 2, CISH negative	19 (15,57)
HER2-positive CPI result 2, CISH positive	2 (1,64)
HER2-positive CPI result 3	13 (10,7)
Conclusion of HER2 expression interpretation, n (%)	
Positive	15 (12,3)
Negative	107 (87,7)

Among HER2-positive tumors, 13 had IHC 3+, and 2 had IHC 2+ confirmed by CISH. The majority (87.7%) were HER2-negative, including IHC 0 (n=57), IHC 1+ (n=31), and IHC 2+ with negative CISH (n=19).

Association with Clinicopathological Features

No significant associations were found between HER2 expression and liver metastasis, tumor location, Borrmann type, differentiation, or Lauren classification (all $p>0.05$). A non-significant trend toward higher HER2 positivity was observed in patients with liver metastasis, intestinal type, moderate differentiation, and Borrmann type I/II (Table 3).

Table 3. The relationship between clinical features, endoscopic features and histopathological features with HER2 expression in gastric adenocarcinoma

Variable	HER2 expression in gastric adenocarcinoma		RP (IK 95%)	p
	Yes	No		
Liver Metastasis, n (%)				
Yes	6 (17,6)	28 (82,4)	1,726 (0,655-4,480)	0,355
No	9 (10,2)	79 (89,8)		
Lesion Location, n (%)				
Non-cardiac (gastric)	8 (12,3)	57 (87,7)	1,002 (0,388-2,591)	1,000
Cardia (gastric)	7 (12,3)	50 (87,7)		
Lesion Type based on Borrmann Classification, n (%)				
Type polypoid (type I) or type fungating carcinoma (type II)	9 (16,1)	47 (83,9)	1,768 (0,670-4,662)	0,250
Type ulcerated (type III) or type diffusely infiltrative (type IV)	6 (9,1)	60 (90,9)		
Tumor differentiation, n (%)				
Well or Moderate Differentiation	7 (14,3)	42 (85,7)	1,304 (0,505-3,363)	0,789
Poor Differentiation	8 (11,0)	65 (89,0)		
Lauren Classification, n (%)				
Intestinal Type	10 (13,9)	62 (86,1)	1,389 (0,505-3,817)	0,524
Diffuse or Mixed Type	5 (10,0)	45 (90,0)		

Chi square test; Fisher Exact Test

HER2 Expression and Survival Analysis

At 24 months, 96 patients (79.5%) had died, 22 (17.2%) were lost to follow-up, and 4 (3.3%) were alive. Most deaths were due to cancer progression (83.3%). Median survival was 5 months in HER2-positive and 4 months in HER2-negative patients, with cumulative survival at 24 months of 0.0% vs. 12.4%, respectively (Figure 2).




Figure 2. Kaplan Meier curve of two-year survival of HER2 expression in gastric adenocarcinoma

Cox regression confirmed no significant association between HER2 and two-year survival (HR 1.12; 95% CI 0.61–2.06; $p=0.716$). Subgroup analysis suggested a trend toward worse outcomes in HER2-positive patients after 10 months, but without statistical significance (HR 3.34; 95% CI 0.90–12.45; $p=0.072$).

Therapeutic Modalities and Survival

Overall, 54.1% received active treatment (surgery, chemotherapy, or combination), while 45.9% received only supportive or palliative care. Multivariate Cox regression identified therapy type as a significant predictor of survival ($p=0.039$). Palliative care was associated with higher mortality (HR 1.55; 95% CI 1.02–2.34), whereas combined surgery and chemotherapy was protective (HR 0.46; 95% CI 0.22–0.95). No significant interaction was observed between HER2 status and treatment effect (Table 4).

Table 4. The type of therapy given to subjects is associated with survival.

Variable	Death		RP (IK 95%)	p
	Yes	No		
Resection and chemotherapy				
No	24 (22,0)	85 (78,0)	0,456 (0,219-0,950)	0,036
Yes	5 (38,5)	8 (61,5)		
Palliative Therapy				
No	16 (24,2)	50 (75,8)	1,547 (1,022-2,343)	0,039
Yes	13 (23,2)	43 (76,8)		

Discussion

This study evaluated the relationship between clinicopathological features, HER2 expression, and survival in gastric adenocarcinoma. HER2 positivity was observed in 12.3% of cases, consistent with reports from Asia (11–16%)^(16,31) and within the global range of 10–30%⁽⁸⁾. Variability in prevalence across studies may reflect differences in methodology, scoring criteria, and tumor biology^(9,12).

No significant associations were found between HER2 expression and liver metastasis, tumor location, morphology, histological type, or differentiation. These findings are in line with several studies^(9,17,32), although others reported significant correlations, particularly with intestinal-type tumors and proximal gastric location^(23,33). The heterogeneity of gastric cancer, both inter and intratumoral, may account for these discrepancies^(34,35).

Regarding prognosis, HER2 status was not significantly associated with two-year survival (HR 1.12; 95% CI 0.61–2.06). Median survival was less than six months in both HER2-positive and negative groups, reflecting the advanced stage and limited treatment options in this cohort. These results are consistent with studies showing HER2 alone may not be an independent prognostic factor^(21,36), but contrast with others linking HER2 positivity to poorer survival⁽¹⁸⁾ or improved outcomes with trastuzumab^(12,22). Differences in treatment patterns are likely to contribute to these variations, as most of our patients received only palliative care.

A non-significant trend toward worse outcomes in HER2-positive patients after 10 months was observed, suggesting HER2 may influence tumor progression, particularly in advanced disease with liver metastasis^(33,37). However, limited sample size and heterogeneous therapies restrict firm conclusions.

Strengths of this study include its multicenter design and use of standardized IHC with confirmatory CISH. Limitations include retrospective design, lack of staging data, and restriction to hospitals in Jakarta, which may limit generalizability. Larger prospective studies with standardized treatment regimens are needed to clarify the prognostic role of HER2 in Indonesian gastric cancer patients.

Conclusion

In this multicenter study of gastric adenocarcinoma patients in Indonesia, HER2 positivity was observed in 12.3% of cases. No significant associations were found between HER2 expression and clinicopathological features, including liver metastasis, tumor location, morphology, differentiation, and Lauren classification. Furthermore, HER2 expression was not associated with two-year survival, with cumulative survival at 24 months being 0.0% in the HER2-positive group compared with 12.4% in the HER2-negative group. These findings suggest that HER2 status alone may not serve as an independent prognostic marker for gastric adenocarcinoma in the Indonesian setting.

Acknowledgments

The authors would like to thank the staff of the Department of Anatomical Pathology, the Endoscopy Unit, and the Medical Record Units of Dr. Cipto Mangunkusumo National Central General Hospital, Gatot Soebroto Army Central Hospital, Fatmawati Central General Hospital, and Dharmais Cancer Hospital, Jakarta, for their assistance in providing access to specimens and clinical data. We also acknowledge the contribution of the laboratory team at the Department of Anatomical Pathology, Faculty of Medicine Universitas Indonesia, for their technical support in performing immunohistochemistry and CISH examinations.

This study did not receive specific financial support from any funding agency or industry. The authors declare no conflicts of interest related to this study.

HER2 Expression and Survival Outcomes in Gastric Adenocarcinoma: Association with Clinical, Endoscopic, and Histopathological Features

ORIGINALITY REPORT

13%

SIMILARITY INDEX

PRIMARY SOURCES

1	www.ncbi.nlm.nih.gov Internet	56 words — 2%
2	www.frontiersin.org Internet	44 words — 1%
3	Hyeongbin Kim, SangHyuk Seo, KwangHee Kim, Yo-Han Park, MinSung An, HyungJoo Baik, ChangSoo Choi, SangHoon Oh. "Prognostic significance of Human epidermal growth factor receptor-2 expression in patients with resectable gastric adenocarcinoma", World Journal of Surgical Oncology, 2019 Crossref	38 words — 1%
4	TUMADER KHOUJA, RACHEL G. MILLER, PAUL A. MOORE, TREVOR J. ORCHARD, TINA COSTACOU. "The Extent of Severe Periodontal Disease as a Predictor of Cardiovascular Complications and Mortality in Type 1 Diabetes (T1D)", Diabetes, 2018 Crossref	23 words — 1%
5	www.science.gov Internet	21 words — 1%
6	Shigenobu Motoshima, Koji Yonemoto, Hideki Kamei, Michi Morita, Rin Yamaguchi. "Prognostic	18 words — 1%

implications of HER2 heterogeneity in gastric cancer",
Oncotarget, 2018

Crossref

7	eje.bioscientifica.com Internet	18 words — 1 %
8	statistik.jakarta.go.id Internet	15 words — < 1 %
9	thejns.org Internet	15 words — < 1 %
10	d.docksci.com Internet	14 words — < 1 %
11	www.scielo.br Internet	13 words — < 1 %
12	ejournal.unisba.ac.id Internet	12 words — < 1 %
13	f1000research.s3.amazonaws.com Internet	12 words — < 1 %
14	pmc.ncbi.nlm.nih.gov Internet	12 words — < 1 %
15	www.koreascience.or.kr Internet	11 words — < 1 %
16	Julia Held, Christoph Schwabl, David Haschka, Sarah Maier et al. "Major cardiovascular events in patients with cardiovascular monosodium urate deposits in atherosclerotic plaques", Rheumatology, 2025 Crossref	10 words — < 1 %

17 Qiu, Miao-zhen, Qian Li, Zhi-qiang Wang, Tian-shu Liu, Qing Liu, Xiao-li Wei, Ying Jin, De-shen Wang, Chao Ren, Long Bai, Dong-sheng Zhang, Feng-hua Wang, Yu-hong Li, and Rui-hua Xu. "HER2-positive patients receiving trastuzumab treatment have a comparable prognosis with HER2-negative advanced gastric cancer patients: A prospective cohort observation", International Journal of Cancer, 2013.

Crossref

18 Qun-Hong Liu, Ju-Xiang Tan, Cai-Xia Hu, Xiao-Pei Zhang, Shu-Ying Liu, Li-Hong Wan. "Relationship of family function and pre-hospital delay among Chinese patients with recurrent ischaemic stroke and the mediation effect of stigma", European Journal of Cardiovascular Nursing, 2023

Crossref

19 link.springer.com 9 words — < 1%

Internet

20 revportcardiol.org 9 words — < 1%

Internet

21 www.nature.com 9 words — < 1%

Internet

22 Sneha Suresh, Alina Khan, Anya Snary, James Pickering, Ruman Rahman, Richard Grundy, Robert Layfield, Farhana Haque. "HGG-48. A comparative proteomic analysis of the cell membrane of histone 3 mutated paediatric high-grade gliomas in order to identify potential immunotherapeutic targets", Neuro-Oncology, 2022

Crossref

23 www.medrxiv.org 8 words — < 1%

Internet

24 www.researchsquare.com

Internet

8 words — < 1%

25

Amira B. Kassem, Ahmad Z. Al Meslamani,
Mohamed AbdElrahman, Nadia Al Mazrouei et al.
"The Impact of a Community Pharmacy-Led Deworming-
Related Counselling Service: An Interventional Study in a Low-
to-Middle Income Country", Tropical Medicine and Infectious
Disease, 2025

Crossref

6 words — < 1%

EXCLUDE QUOTES	OFF	EXCLUDE SOURCES	OFF
EXCLUDE BIBLIOGRAPHY	OFF	EXCLUDE MATCHES	OFF